Cytosorbents (CTSO) Projected to Post Earnings on Wednesday

Cytosorbents (NASDAQ:CTSO - Get Free Report) is anticipated to post its Q1 2025 quarterly earnings results after the market closes on Wednesday, May 14th. Analysts expect Cytosorbents to post earnings of ($0.08) per share and revenue of $9.01 million for the quarter.

Cytosorbents (NASDAQ:CTSO - Get Free Report) last issued its earnings results on Monday, March 31st. The medical research company reported ($0.03) EPS for the quarter, beating analysts' consensus estimates of ($0.07) by $0.04. The business had revenue of $9.20 million during the quarter, compared to analyst estimates of $10.09 million. Cytosorbents had a negative return on equity of 118.54% and a negative net margin of 49.47%. On average, analysts expect Cytosorbents to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Cytosorbents Trading Down 2.0 %

NASDAQ CTSO opened at $0.89 on Wednesday. The business has a 50 day moving average price of $1.03 and a 200-day moving average price of $1.00. Cytosorbents has a 52 week low of $0.70 and a 52 week high of $1.61. The company has a quick ratio of 1.58, a current ratio of 1.97 and a debt-to-equity ratio of 1.06. The company has a market cap of $55.72 million, a price-to-earnings ratio of -2.47 and a beta of 1.17.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the company. StockNews.com initiated coverage on Cytosorbents in a report on Monday. They set a "hold" rating for the company. HC Wainwright restated a "neutral" rating and set a $1.00 price target on shares of Cytosorbents in a report on Thursday, April 3rd. Finally, D. Boral Capital restated a "buy" rating and issued a $10.00 target price on shares of Cytosorbents in a research note on Friday, May 2nd. Two analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $4.67.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.